Scholarlink

Purpose of Review <p>To summarize novel insights regarding the independent and combined roles of triglyceride-rich lipoprotein elevations and low-grade inflammation in cardiovascular disease.</p> Recent Findings <p>Emerging evidence suggest that triglyceride-rich lipoproteins are more atherogenic than LDL particles, and that remnant cholesterol drives the association with cardiovascular risk. In contemporary secondary prevention, elevated hsCRP is a stronger predicter of cardiovascular events than LDL cholesterol, while in primary prevention, hsCRP and LDL cholesterol equally predict risk of future cardiovascular disease. Some anti-inflammatory trials do not support the use of colchicine in acute coronary syndrome; however, results from recent meta-analyses strongly support colchicine therapy for secondary cardiovascular prevention. Finally, epidemiological and genetic studies indicate that triglyceride-rich lipoproteins cause vascular inflammation, although both risk factors appear to contribute synergistically to cardiovascular risk.</p> Summary <p>Triglyceride-rich lipoprotein elevations and low-grade inflammation are important, independent cardiovascular risk factors. More research is needed to further characterize their potential interplay in cardiovascular disease and validate never therapies.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Triglyceride-Rich Lipoproteins and Inflammation: Independent and Synergistic Roles in Cardiovascular Disease

  • 期刊论文

  • 发表日期：

    2026年3月2日

查看全文
  • Ask Tybjærg Nordestgaard

摘要

Purpose of Review

To summarize novel insights regarding the independent and combined roles of triglyceride-rich lipoprotein elevations and low-grade inflammation in cardiovascular disease.

Recent Findings

Emerging evidence suggest that triglyceride-rich lipoproteins are more atherogenic than LDL particles, and that remnant cholesterol drives the association with cardiovascular risk. In contemporary secondary prevention, elevated hsCRP is a stronger predicter of cardiovascular events than LDL cholesterol, while in primary prevention, hsCRP and LDL cholesterol equally predict risk of future cardiovascular disease. Some anti-inflammatory trials do not support the use of colchicine in acute coronary syndrome; however, results from recent meta-analyses strongly support colchicine therapy for secondary cardiovascular prevention. Finally, epidemiological and genetic studies indicate that triglyceride-rich lipoproteins cause vascular inflammation, although both risk factors appear to contribute synergistically to cardiovascular risk.

Summary

Triglyceride-rich lipoprotein elevations and low-grade inflammation are important, independent cardiovascular risk factors. More research is needed to further characterize their potential interplay in cardiovascular disease and validate never therapies.